Table 1.
Detailed patient information with individual pharmacokinetic parameters (AUC(0,t) and CL) for APAP
| Patient number | Route of administration | *Dose kg–1 | Post-menstrual age (weeks) | Body weight (kg) | Gender | †AUC(0-t) (ng ml–1 h) | †‡CL (l h–1) |
|---|---|---|---|---|---|---|---|
| AH15 | i.v. | 6 ng | 44.9 | 3.0 | M | 0.0261 | 0.6848 |
| AH17 | i.v. | 6 ng | 73.7 | 8.0 | F | 0.0234 | 2.0815 |
| AH19 | i.v. | 6 ng | 36.3 | 2.6 | F | 0.0255 | 0.6166 |
| AH21 | i.v. | 6 ng | 127.0 | 9.8 | F | 0.0200 | 2.8451 |
| AH23 | i.v. | 6 ng | 42.9 | 5.1 | F | 0.0234 | 1.2721 |
| AH35 | i.v. | 6 ng | 35.6 | 3.0 | M | 0.0058 | 3.0660 |
| AH14 | Oral | 6 ng | 39.1 | 2.3 | M | 0.0174 | 0.7941 |
| AH16 | Oral | 6 ng | 75.4 | 5.5 | F | 0.0111 | 2.9355 |
| AH18 | Oral | 6 ng | 44.1 | 2.9 | M | 0.0211 | 0.8228 |
| AH20 | Oral | 6 ng | 77.0 | 6.3 | F | 0.0294 | 1.2887 |
| AH01 | i.v. | 7.4mg | 41.0 | 3.4 | F | 18964.88 | 1.3182 |
| AH03 | i.v. | 14.9mg | 57.7 | 6.7 | F | 46125.36 | 2.1680 |
| AH05 | i.v. | 14.1mg | 75.4 | 7.1 | M | 53037.72 | 1.8855 |
| AH08 | i.v. | 15.0mg | 76.3 | 8 | M | 63645.26 | 1.8855 |
| AH09 | i.v. | 15.0mg | 86.0 | 10 | M | 50845.19 | 2.9501 |
| AH10 | i.v. | 15.0mg | 79.3 | 5.9 | M | 55117.83 | 1.6329 |
| AH12 | i.v. | 20.0mg | 38.6 | 2.6 | F | 15527.7 | 1.2880 |
| AH13 | i.v. | 7.8mg | 39.9 | 3.2 | M | 30322.2 | 0.8245 |
| AH24 | i.v. | 14.1mg | 66.9 | 6.4 | F | 43440.96 | 2.0718 |
| AH25 | i.v. | 14.8mg | 52.0 | 4.1 | F | 21867.59 | 2.7438 |
| AH26 | i.v. | 7.1mg | 40.1 | 3.5 | M | 13069.82 | 1.9128 |
| AH27 | i.v. | 7.0mg | 41.3 | 3.6 | M | 8119.676 | 3.0789 |
| AH28 | i.v. | 7.4mg | 38.6 | 3.2 | M | 11855.91 | 2.0243 |
| AH29 | i.v. | 15.2mg | 49.1 | 3.3 | M | 19569.3 | 2.5550 |
| AH31 | i.v. | 7.3mg | 41.9 | 3.7 | F | 11848.15 | 2.2788 |
| TP09 | i.v. | 8.0mg | 36.0 | 3.9 | F | 2069.503 | 14.4962 |
| TP13 | i.v. | 9.0mg | 36.0 | 2.3 | F | 18410.7 | 1.0863 |
| AH02 | Oral | 7.2mg | 38 | 2.5 | M | 134629.9 | 0.4457 |
| AH04 | Oral | 15.4mg | 79.4 | 7.8 | F | 41954.4 | 2.8602 |
| AH06 | Oral | 15.0mg | 68.7 | 6.0 | M | 40109.02 | 2.2439 |
| AH11 | Oral | 13.6mg | 52.1 | 4.4 | M | 11495.91 | 1.5658 |
| AH32 | Oral | 15.0mg | 50.9 | 5.0 | F | 15655.72 | 4.7906 |
| AH33 | Oral | 15.0mg | 43.6 | 4.0 | M | 12051.86 | 4.9785 |
*Infants were administered either a) 111 Bq kg–1 [14C]-PARA as a microdose (6 ng kg–1) or b) a microtracer dose alongside the therapeutic dose listed in the table.
†Individual AUC(0-t) and CL values based on dose of PARA administered.
‡Apparent clearance (CL/F) was obtained for oral route.